When I started Dante Labs, the premise was simple: give people access to their complete genome — not a fraction of it, not a consumer approximation, but the entire thing — and do it at a price that didn't require a research grant. That premise hasn't changed. But we have.
I'm writing this because we owe you an honest account of where we've been, what we've learned, and what we're building now. Not a press release. A direct conversation.
What we heard
Over the past two years, we listened — to customers, to physicians, to the clinical genetics community, and to the people who tried Dante Labs and felt let down. Some of what we heard was difficult. Delivery timelines that weren't met. Communication that wasn't clear enough. A product experience that didn't match the quality of the science behind it.
That gap — between the caliber of our sequencing and the quality of the experience around it — was real. And it was ours to fix.
What we did about it
We didn't make adjustments. We changed everything.
The website you're reading this on is new. Not a redesign — a rethinking of how we present what we do and who we do it for. Every page, every word, every clinical claim on this site was rewritten with one filter: does this help someone make a better decision about their health?
Behind the scenes, the changes go deeper:
- Our laboratory partner in Italy — operating under ISO 15189 medical laboratory accreditation — processes every genome under GDPR, the strongest data protection framework in the world. This is not new, but we've never explained it clearly enough. We are now.
- Our reporting platform now delivers 200+ clinical-grade reports organized by category, written for physicians, and accessible to patients. These reports update automatically as new variant-disease associations are validated.
- Our customer experience — from order to results — has been redesigned around clarity, reliability, and respect for the weight of what we're delivering.
What hasn't changed
The science. 30X whole genome sequencing at 99.98% accuracy. Every gene, every variant, every region between genes. The same clinical standard used in diagnostic laboratories and academic medical centers. We've sequenced over 100,000 genomes. The sequencing was never the problem.
The mission hasn't changed either. I still believe that every person should have access to their complete genetic information — and that this information should be protected by law, not by corporate policy. Our laboratory sits in the European Union. Your genome is processed under GDPR. That is a jurisdictional fact, not a marketing claim. And after watching what happened at 23andMe, I believe it matters more than ever.
Why this moment matters
The genomics industry is at an inflection point. Costs are falling. The science is accelerating. And consumer trust — after years of overpromising and under-delivering across the industry — is fragile.
I don't think the answer is more marketing. I think the answer is better work. Clearer communication. Faster results. Reports that physicians actually use. And absolute honesty about what whole genome sequencing can and cannot do.
We're not perfect. We're not going to claim to be. But we are doing the work — every day — to earn the trust that genomic medicine requires.
What comes next
We're building Dante Labs for the next decade of genomic medicine. A platform where your genome is sequenced once and becomes more valuable every year as science advances. Where your data is protected by the strongest legal framework in the world. Where the reports your doctor receives meet the same standard as those from the best academic medical centers.
If you've been with us from the beginning, thank you. If you're discovering us for the first time, welcome. And if you tried Dante Labs before and it didn't meet your expectations — I'd ask you to look at what's different now.
The most important information about your health has always been in your DNA. We're here to help you read it.
Andrea Riposati CEO, Dante Labs
Get new posts from Dante Labs
Genomics insights, product updates, and clinical perspectives — delivered to your inbox.
